RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Celyad Oncology Stock

Celyad Oncology EBIT 2024

Celyad Oncology EBIT

-10.67 M EUR

Ticker

CYAD.BR

ISIN

BE0974260896

WKN

A1W7Q9

In 2024, Celyad Oncology's EBIT was -10.67 M EUR, a 11.84% increase from the -9.54 M EUR EBIT recorded in the previous year.

The Celyad Oncology EBIT history

YEAREBIT (undefined EUR)
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-
2010-

Celyad Oncology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Celyad Oncology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Celyad Oncology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Celyad Oncology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Celyad Oncology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Celyad Oncology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Celyad Oncology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Celyad Oncology’s growth potential.

Celyad Oncology Revenue, EBIT and net profit per share

DateCelyad Oncology RevenueCelyad Oncology EBITCelyad Oncology Net Income
2025e156.25 M undefined-13.81 M undefined15.41 M undefined
2024e62.5 M undefined-10.67 M undefined20.21 M undefined
2023102,000 undefined-9.54 M undefined-8.45 M undefined
20220 undefined-5.77 M undefined-40.94 M undefined
20210 undefined-26.39 M undefined-26.51 M undefined
20205,000 undefined-16.98 M undefined-17.2 M undefined
20196,000 undefined-28.88 M undefined-28.63 M undefined
20183.12 M undefined-37.99 M undefined-37.43 M undefined
20173.54 M undefined-26.6 M undefined-56.4 M undefined
20168.52 M undefined-25.61 M undefined-23.61 M undefined
20153,000 undefined-29.67 M undefined-29.11 M undefined
2014146,000 undefined-16.44 M undefined-16.45 M undefined
20130 undefined-12.95 M undefined-14.49 M undefined
201250,000 undefined-12.9 M undefined-13.52 M undefined
20110 undefined-9.3 M undefined-9.35 M undefined
20101.52 M undefined-6.42 M undefined-6.71 M undefined

Celyad Oncology stock margins

The Celyad Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Celyad Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Celyad Oncology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Celyad Oncology's sales revenue. A higher gross margin percentage indicates that the Celyad Oncology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Celyad Oncology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Celyad Oncology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Celyad Oncology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Celyad Oncology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Celyad Oncology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Celyad Oncology Margin History

Celyad Oncology Gross marginCelyad Oncology Profit marginCelyad Oncology EBIT marginCelyad Oncology Profit margin
2025e32.35 %-8.84 %9.86 %
2024e32.35 %-17.08 %32.34 %
202332.35 %-9,356.86 %-8,282.35 %
202232.35 %0 %0 %
202132.35 %0 %0 %
2020100 %-339,540 %-344,080.03 %
2019100 %-481,316.65 %-477,200 %
2018100 %-1,219.52 %-1,201.51 %
201785.45 %-751.5 %-1,593.08 %
201699.38 %-300.47 %-276.97 %
201566.67 %-989,066.7 %-970,466.7 %
2014-8,407.53 %-11,258.22 %-11,269.18 %
201332.35 %0 %0 %
2012-11,320 %-25,800 %-27,040 %
201132.35 %0 %0 %
2010-109.87 %-422.37 %-441.45 %

Celyad Oncology Aktienanalyse

What does Celyad Oncology do?

Celyad Oncology is a biotech company specializing in the discovery and development of new cancer immunotherapies. The company, headquartered in Mont-Saint-Guibert, Belgium, was founded in 2007 and has been listed on the NASDAQ and Euronext stock exchanges since September 2015. The history of Celyad Oncology began with the discovery of CAR-T therapy, which is based on the tumor cell recognition by T cells of the body's immune system. In 2001, researchers at the University of Leuven (Belgium) introduced a new method for culturing T cells, which was a major step in the development of CAR-T therapy. In 2004, the researchers founded Celyad with the aim of developing clinically effective CAR-T therapies. In 2015, the company was renamed Celyad Oncology to emphasize its strategic focus on oncology products. Celyad Oncology has developed a unique business model that focuses on the clinical development of CAR-T cell therapies. The company uses innovative technologies such as allogeneic CAR-T cells, which come from donor tissue from persons other than the patient. These cells have the advantage of being able to be produced in unlimited quantities, enabling the rapid and cost-effective manufacturing of CAR-T cells. In addition, the company has developed a platform technology called "shRNA" that regulates gene expression in T cells, thereby improving the safety and efficacy of CAR-T therapies. The company is divided into various divisions, from preclinical research to the clinical development and commercialization of CAR-T therapies. Celyad Oncology has several product candidates in various stages of development, focusing on indications such as multiple myeloma, acute myeloid leukemia (AML), and solid tumors. One of Celyad Oncology's most promising product candidates is CYAD-01, a CAR-T cell product targeting the CD19 protein. It is currently in a Phase I/IIa clinical trial evaluating the safety and efficacy of CYAD-01 in patients with refractory or relapsed CD19+ B-cell lymphoma. In October 2020, the product candidate achieved a complete response in a patient with a different indication, acute myeloid leukemia (AML). Another product candidate is CYAD-101, an allogeneic CAR-T cell product targeting the NKG2D protein. This protein is overexpressed on many cancer cells but not on healthy cells. CYAD-101 is currently in a Phase I/II clinical trial for the treatment of various tumor types, including lung cancer and pancreatic cancer. Celyad Oncology also collaborates with other companies to further develop its technologies and product candidates. In 2018, the company entered into a partnership with Novartis to utilize Celyad Oncology's CAR-T platform technology for the development of products for solid tumors. In 2019, Celyad Oncology announced a partnership with ONO Pharmaceutical to accelerate the development of CYAD-211, an allogeneic CAR-T cell product for the treatment of multiple myeloma. In summary, Celyad Oncology has not only a unique business model but also promising product candidates and technologies that have the potential to revolutionize the treatment of cancer. With a strong pipeline and targeted clinical development, Celyad Oncology is well positioned to continue its success in the future. Celyad Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Celyad Oncology's EBIT

Celyad Oncology's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Celyad Oncology's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Celyad Oncology's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Celyad Oncology’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Celyad Oncology stock

How much did Celyad Oncology achieve in EBIT for the current year?

In the current year, Celyad Oncology has achieved an EBIT of -10.67 M EUR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Celyad Oncology.

How has the EBIT of Celyad Oncology developed in recent years?

The EBIT of Celyad Oncology has increased by 11.838% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Celyad Oncology?

The EBIT of Celyad Oncology is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Celyad Oncology pay?

Over the past 12 months, Celyad Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celyad Oncology is expected to pay a dividend of 0 EUR.

What is the dividend yield of Celyad Oncology?

The current dividend yield of Celyad Oncology is .

When does Celyad Oncology pay dividends?

Celyad Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Celyad Oncology?

Celyad Oncology paid dividends every year for the past 0 years.

What is the dividend of Celyad Oncology?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Celyad Oncology located?

Celyad Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Celyad Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Celyad Oncology from 10/2/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Celyad Oncology pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Celyad Oncology in the year 2023?

In the year 2023, Celyad Oncology distributed 0 EUR as dividends.

In which currency does Celyad Oncology pay out the dividend?

The dividends of Celyad Oncology are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Celyad Oncology

Our stock analysis for Celyad Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celyad Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.